All In Biotech

NDA 021036 · Glaxosmithkline

Relenza

Zanamivir · Inhalation · Neuraminidase Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Oct 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Jul 26, 1999

Approved uses

4

Original approval plus efficacy supplements

Registered trials

22

7 Phase 3, 3 recruiting

FAERS reports

2,525

1,595 serious, 250 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 23, 2026.

RELENZA, an influenza virus neuraminidase inhibitor (NAI), is indicated for: Treatment of acute, uncomplicated influenza type A and B infections in patients aged 7 years and older who have been symptomatic for no more than 2 days. ( 1.1 ) Prophylaxis of influenza in patients aged 5 years and older. ( 1.2 ) Important Limitations of Use: Not recommended for treatment or prophylaxis of influenza in: • Individuals with underlying airways disease. ( 5.1 ) Not proven effective for: • Treatment in individuals with underlying airways disease. ( 1.3 ) • Prophylaxis in nursing home residents. ( 1.3 ) Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RELENZA. ( 1.3 ) 1.1 Treatment of Influenza RELENZA (zanamivir) inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days. 1.2 Prophylaxis of Influenza RELENZA is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older. 1.3 Important Limitations of Use • RELENZA is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) due to risk of serious bronchospasm [see Warnings and Precautions ( 5.1 )] . • RELENZA has not been proven effective for treatment of influenza in individuals with underlying airways disease. • RELENZA has not been proven effective for prophylaxis of influenza in the nursing home setting. • RELENZA is not a substitute for early influenza vaccination on an annual basis as recommended by the...

Mechanism: Zanamivir is an antiviral drug with activity against influenza virus [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 29, 2006 Supplement 8 · Efficacy · priority review LabelReviewLetter
  • Mar 29, 2006 Supplement 9 · Efficacy · priority review
  • Apr 26, 2000 Supplement 1 · Efficacy · priority review ReviewLetterLabel
  • Jul 26, 1999 Original approval · Type 1 - New Molecular Entity · priority review LetterLabelReview
1 products under this application
  • RELENZA · ZANAMIVIR 5MG · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Zanamivir" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • abnormal behaviour399
  • overdose395
  • drug exposure during pregnancy244
  • hallucination159
  • drug exposure via breast milk123
  • no adverse event117
  • delirium115
  • loss of consciousness104
  • pyrexia100
  • death70
  • dyspnoea69
  • aggression57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20058
20066
2007113
2008143
2009933
2010312
2011317
201291
201360
2014114
201578
201677
201732
201849
201994
202044
202124
20228
20237
20245
20255
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Relenza (Zanamivir)

2024 spending

$13K

Beneficiaries

114

194 claims

Per beneficiary

$113

$2.89 per unit

View as table
YearSpending
2020$31,974
2021$11,647
2022$16,311
2023$13,400
2024$12,885

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 126 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.